tetano
Editor, Senior Moderator
Diabet Med. 2011 Jul;28(7):815-7. doi: 10.1111/j.1464-5491.2011.03255.x.
The humoral immune response to the inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with Type 2 diabetes mellitus in Korea.
Nam JS, Kim AR, Yoon JC, Byun Y, Kim SA, Kim KR, Cho S, Seong BL, Ahn CW, Lee JM.
Source
Department of Internal Medicine Department of Microbiology and Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine Department of Biotechnology, Yonsei University College of Life Science and Biotechnology Severance Institute for Vascular and Metabolic Research, Seoul, Korea.
Abstract
Diabet. Med. 28, 815-817 (2011) ABSTRACT: Aims We evaluated the antibody response to a single-dose adjuvanted, inactivated, pandemic H1N1 influenza vaccination in patients with diabetes and assessed factors associated with the failure to induce antibody responses. Methods Eighty-two patients with Type 2 diabetes were vaccinated and antibody responses were determined with haemagglutination inhibition assay and anti-haemagglutinin antibody ELISA. Results Among 70 antibody-negative patients at baseline, 34 (48.6%) achieved seroconversion; 28 (60.9%) in the young adults group and six (25%) in the elderly group acquired H1N1-specific antibodies. Patients in the older age range or with longer duration of diabetes had a lower seroconversion rate. Conclusions Our data show low cross-reactive antibody carrying rate and low seroconversion rate in patients with diabetes. Until larger-scale, case-controlled trials become available, older patients and patients with a longer duration of diabetes should be considered for the two-dose vaccination or have antibody titres measured after the first vaccination.
? 2011 The Authors. Diabetic Medicine ? 2011 Diabetes UK.
PMID:
21672004
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/21672004
The humoral immune response to the inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with Type 2 diabetes mellitus in Korea.
Nam JS, Kim AR, Yoon JC, Byun Y, Kim SA, Kim KR, Cho S, Seong BL, Ahn CW, Lee JM.
Source
Department of Internal Medicine Department of Microbiology and Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine Department of Biotechnology, Yonsei University College of Life Science and Biotechnology Severance Institute for Vascular and Metabolic Research, Seoul, Korea.
Abstract
Diabet. Med. 28, 815-817 (2011) ABSTRACT: Aims We evaluated the antibody response to a single-dose adjuvanted, inactivated, pandemic H1N1 influenza vaccination in patients with diabetes and assessed factors associated with the failure to induce antibody responses. Methods Eighty-two patients with Type 2 diabetes were vaccinated and antibody responses were determined with haemagglutination inhibition assay and anti-haemagglutinin antibody ELISA. Results Among 70 antibody-negative patients at baseline, 34 (48.6%) achieved seroconversion; 28 (60.9%) in the young adults group and six (25%) in the elderly group acquired H1N1-specific antibodies. Patients in the older age range or with longer duration of diabetes had a lower seroconversion rate. Conclusions Our data show low cross-reactive antibody carrying rate and low seroconversion rate in patients with diabetes. Until larger-scale, case-controlled trials become available, older patients and patients with a longer duration of diabetes should be considered for the two-dose vaccination or have antibody titres measured after the first vaccination.
? 2011 The Authors. Diabetic Medicine ? 2011 Diabetes UK.
PMID:
21672004
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/21672004